Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.

Staber, PB; Jurczak, W; Greil, R; Vucinic, V; Middeke, JM; Montillo, M; Munir, T; Neumeister, P; Schetelig, J; Stilgenbauer, S; Striebel, F; Dirnberger-Hertweck, M; Weirather, J; Brugger, W; Kelemen, P; Wendtner, CM; Woyach, JA; Leuk Lymphoma. 2021; 62(14): 3440-3451.

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

Kreissl, S; Goergen, H; Buehnen, I; Kobe, C; Moccia, A; Greil, R; Eichenauer, DA; Zijlstr, JM; Markova, J; Meissner, J; Feuring-Buske, M; Soekler, M; Beck, HJ; Willenbacher, W; Ludwig, WD; Pabst, T; Topp, MS; Hitz, F; Bentz, M; Keller, UB; Kuhnhardt, D; Ostermann, H; Hertenstein, B; Ulitzky, WA; Maschmeyer, G; Vieler, T; Eich, H; Baues, C; Stein, H; Fuchs, M; Diehl, V; Dietlein, M; Engert, A; Borchmann, P LANCET HAEMATOL. 2021; 8(6): e398-e409.

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Greil, R; Tedeschi, A; Moreno, C; Anz, B; Larratt, L; Simkovic, M; Gill, D; Gribben, JG; Flinn, IW; Wang, ZY; Cheung, LWK; Nguyen, AN; Zhou, C; Styles, L; Demirkan, F ANN HEMATOL. 2021; 100(7): 1733-1742.

SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining.

Akimova, E; Gassner, FJ; Schubert, M; Rebhandl, S; Arzt, C; Rauscher, S; Tober, V; Zaborsky, N; Greil, R; Geisberger, R NUCLEIC ACIDS RES. 2021; 49(5): 2598-2608.

Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators.

Rauscher, S; Greil, R; Geisberger, R CURR CANCER DRUG TAR. 2021; 21(4): 353-359.

Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stoger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R BREAST CARE. 2021;

AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL.

Schubert, M; Gassner, FJ; Huemer, M; Hopner, JP; Akimova, E; Steiner, M; Egle, A; Greil, R; Zaborsky, N; Geisberger, R CANCERS. 2021; 13(11):

Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Gampenrieder, SP; Steiner, M; Hufnagl, C; Hackl, H; Rinnerthaler, G; Westphal, T; Huemer, F; Monzo-Fuentes, C; Morre, P; Hauser-Kronberger, C; Greil, R ANN ONCOL. 2022; 33: S141-S141.

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).

Van Cutsem, E; Eefsen, RL; Ochsenreither, S; Zvirbule, Z; Ivanauskas, A; Arnold, D; Baltruskeviciene, E; Pfeiffer, P; Yachnin, J; Garcia Carbonero, R; Greil, R; Jungels, C; Poulsen, L; Awada, A; Garcia Ribas, I; Losic, N; Collignon, J J CLIN ONCOL. 2022; 40(16):

Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study

Dietrich, S; Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, J; Trneny, M; Sharman, JP; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, Y; Greil, R; Mykhalska, L; Burgues, JMB; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Abrisqueta, P; Gau, JP; Hirata, J; Jiang, Y; Yan, M; Lee, C; Flowers, C; Salles, G ONCOL RES TREAT. 2022; 45(SUPPL 2): 193-194.